Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
复制标题
DOI：
10.1007/s00345-007-0213-4
复制
发表时间：
2007-12
影响因子：
3.4
通讯作者：
Knowles MA
中科院分区：
文献类型：
--
作者：
Knowles MA
尽管非侵袭性膀胱肿瘤（pTa）是最常见的膀胱肿瘤，但直到最近，关于其分子生物学的信息相对较少。因此，当FGF受体3 （FGFR3）突变在膀胱肿瘤中被鉴定出来时，这是非常有趣的，很明显，这些突变在低级别和分期的肿瘤中最常见。自FGFR3激活突变的最初描述以来，已经有大量研究证实了这些突变在所有级别和阶段的膀胱癌中的频率和频谱。突变筛选技术不断发展和改进。FGFR3突变已被评估为肿瘤组织中的预测性生物标志物和尿液中的诊断性生物标志物。人们已经努力了解FGFR3在尿路上皮细胞和其他细胞中的功能。尽管我们对FGFR3功能的了解尚不完整，但已经很明显，它可能不仅是非侵袭性膀胱癌，而且在大量侵袭性肿瘤中都是一个重要的治疗靶点。本文综述了这种有趣的受体在尿路上皮癌（UC）中的现状。
Although non-invasive bladder tumours (pTa) are the most common group of bladder tumours at presentation, there has until recently been relatively little information on their molecular biology. Thus it was of great interest when mutations in the FGF receptor 3 (FGFR3) were identified in bladder tumours and it became apparent that these were most common in tumours of low grade and stage. Since the initial description of activating mutations of FGFR3, there have been numerous studies confirming the frequency and spectrum of these mutations in bladder cancers of all grades and stages. Mutation screening techniques have evolved and improved. FGFR3 mutation has been assessed as a predictive biomarker in tumour tissues and as a diagnostic biomarker in urine. Efforts have been made to understand the function of FGFR3 in urothelial and other cells. Although our understanding of FGFR3 function is incomplete, it is already apparent that this may represent an important therapeutic target not only in non-invasive bladder cancer but also in a significant number of invasive tumours. This review summarises the current state of knowledge of this interesting receptor in urothelial carcinoma (UC).